Colossal is a genetics and biosciences company that creates radical new technologies to advance the field of genomics. Combining the science of genetics with the business of discovery, the company builds technologies for species restoration, endangered species protection, and the repopulation of critical ecosystems that support the continuation of life on Earth. The company has a team of experienced, world-class scientists who address issues related to loss in biodiversity and overall species counts resulting from the human-accelerated degradation of land, sea, and air.
The new funding round was led by United States Innovative Technology Fund, with participation from Breyer Capital, WestRiver Group, Bob Nelsen, Animal Capital, Victor Vescovo, In-Q-Tel, Animoca Brands, Peak 6, BOLD Capital, and Jazz Ventures. The company plans to use the funding to continue to advance genetic engineering and new software, necessary for species de-extinction, conservation, and human healthcare.
Colossal Biosciences, Texas, United States, was founded by Ben Lamm and world-renowned geneticist and serial biotech founder George Church in 2021. As part of its Series B, the company has also announced the launch of its Avian Genomics Group, which will pursue the de-extinction of the Dodo, a bird species that was wiped out of its native ecosystem, Mauritius, as a direct result of human settlement and ecosystem competition. “Genetic technologies are already protecting us and our food sources from infectious and inherited diseases. A society embracing endangered and extinct gene variants is one poised to address many practical obstacles and opportunities in carbon sequestration, nutrition, and new materials. I am pleased with our company’s progress across multiple vertebrate species,” noted George Church, co-founder of Colossal.
